David Hansen, President and CEO

Mr. Hansen is a senior corporate executive with diverse and in-depth experience in the biopharmaceutical business. David has proven leadership abilities in creating, building, and directing small start-up operations and key departments in both large and small biopharmaceutical companies. He has broad therapeutic area expertise including oncology and immunology. He has had direct responsibility for corporate and commercial development functions including in and out licensing, product acquisition, strategic planning and new product planning. Most recently, Mr. Hansen was Senior Vice President of Corporate Development at AVANIR Pharmaceuticals, a company focused on develop on developing and commercializing novel therapeutic products for the treatment of chronic diseases. Prior to that David was a founder, President, and COO of Xenerex Biosciences, a monoclonal antibody company focusing on development of fully human antibody products.

Philip Livingston, M.D., Chief Science Officer

Dr. Livingston is a member and Attending Physician, Melanoma and Sarcoma Service, Department of Medicine at Memorial Sloan-Kettering Cancer Center. He is the Head of the Laboratory of Tumor Vaccinology at MSKCC where Dr. Livingston has treated cancer patients and conducted research for the past 31 years. He is a Professor of Medicine at the Weill Graduate School of Medical Sciences of Cornell University. It is Dr. Livingston’s, patents and associated intellectual property that MabVax will be licensing from MSKCC. Dr. Livingston has led the development of multiple cancer vaccine therapies and has extensively published in the subject area. His work continues to be supported by grants from the National Institutes of Health, MSKCC, the US Army, and the Breast Cancer Research Foundation.

Dr. Douglas Lind, M.D., Managing Partner- GBP Capital

Douglas Lind, managing partner at GBP Capital, has more than 20 years of experience in a variety of life science related professions, ranging from former practicing physician to senior Wall Street equity research analyst. Most recently, he was Founder and Managing Partner of Accendx Management, LLC, a Greenwich, CT based public equity fund formed in 2003. Prior, he was senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. Previously, he was founder and Managing Director of Lind & Co., a Boston-based biotechnology investment research firm. He is a former Tufts University Clinical Fellow in Medicine and a past member of the American Medical Association Council on Ethical and Judicial Affairs. He has served on numerous national health policy bodies, including the Health Policy Agenda for the American People and the American Medical Association Task Force on Physician Manpower. Dr. Lind is a graduate of the University of Iowa College of Medicine, 1987. From 1990 to 1992, he was a practicing physician in Brookline, Massachusetts. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed his residency training in Internal Medicine.

Nicholas Stevens, Partner and Portfolio Manager Edgewood Management LLC

Nick joined Edgewood Management in 1984 as an analyst after three years at Coopers & Lybrand as a management consultant. He became a Partner in 1986 and was given portfolio management responsibilities in 1987. He is on the firm’s investment committee. Nick graduated from Bennington College in 1977 with a B.A. in Literature and from Columbia University Graduate School of Business in 1981 with an M.B.A. in Finance. He is co-head of the Investment Committee of the Reformed Church of Bronxville. Nick also serves on the board of the Greater New York Cystic Fibrosis Foundation and Lawrence Hospital Center in Bronxville, New York.